Hyperbaric Oxygen Shows Limited Benefits for Severe Perianal Crohn's Disease
Mayo Clinic study finds hyperbaric oxygen therapy provides temporary symptom relief but limited long-term healing for refractory perianal Crohn's disease.
Summary
A Mayo Clinic retrospective study examined hyperbaric oxygen therapy (HBOT) in six patients with refractory perianal Crohn's disease. While four patients reported symptomatic improvement, only one showed objective healing on examination. Most patients experienced disease progression and required surgery within a year, suggesting HBOT provides temporary relief but limited long-term benefits for this challenging condition.
Detailed Summary
Perianal Crohn's disease affects approximately 20% of Crohn's patients and remains one of the most challenging manifestations to treat, with up to 80% experiencing refractory or recurrent disease despite advanced biologic therapies. This Mayo Clinic study represents one of the largest case series examining hyperbaric oxygen therapy (HBOT) as a potential treatment option.
Researchers retrospectively analyzed six patients aged 19-60 years who received HBOT for refractory perianal Crohn's disease between 2014-2023. Most patients had severe disease requiring fecal diversion and were on immunosuppressive medications including biologics. Treatment regimens varied from 10-40 HBOT sessions.
The results showed mixed outcomes: four patients reported subjective symptom improvement, but only one demonstrated objective healing on physical examination or imaging. Importantly, disease progression occurred in most patients, with all but one requiring surgical intervention within the following year. Two patients had previous total proctocolectomy with ileal-anal pouch anastomosis, highlighting the severity of cases referred for HBOT.
The theoretical basis for HBOT involves addressing tissue hypoxia, which may contribute to chronic inflammation and poor wound healing in perianal Crohn's disease. By increasing tissue oxygen saturation, HBOT aims to promote repair and reduce local inflammation. However, the relationship between hypoxia and inflammatory bowel disease is complex, with some research suggesting hypoxia may actually have anti-inflammatory effects.
These findings suggest HBOT may offer temporary symptomatic relief for carefully selected patients with severe, refractory perianal Crohn's disease, but it appears insufficient as a standalone therapy for achieving durable remission. The treatment's role may be better suited as an adjunct to standard medical therapy rather than a primary intervention.
Key Findings
- Four of six patients reported symptomatic improvement with HBOT treatment
- Only one patient showed objective healing on examination or imaging
- Most patients experienced disease progression requiring surgery within one year
- Treatment sessions ranged from 10-40 sessions with variable protocols
- HBOT appears to provide temporary relief but limited long-term healing
Methodology
Retrospective case series of six patients treated at Mayo Clinic Rochester between 2014-2023. Patients identified through institutional databases using ICD and CPT codes for Crohn's disease and hyperbaric oxygen therapy.
Study Limitations
Small sample size, heterogeneous patient population and treatment protocols, lack of standardized outcome measures, and absence of control group limit generalizability. Longer follow-up and randomized controlled trials needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.